Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.

Date publication

mars 2019

Journal

Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr FEUGIER Pierre , Pr NERICH Virginie

Tous les auteurs :
Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais-Guillaumot F, Damaj G, Nerich V, Jais JP, Laborde L, Salles G, Henry-Amar M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30901086

Résumé

Long-term survivors of non-Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health-related quality of life. Little is known about the risk-to-benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long-term fatigue levels was investigated in a cross-sectional study.

Mots clés

cross-sectional study, long-term fatigue, long-term survivors, non-Hodgkin lymphomas, risk factors

Référence

Cancer. 2019 Mar 22;: